查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571730

青蒿素联合治疗市场规模、份额、趋势分析报告：按类型、地区、细分市场预测，2024-2030

Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

青蒿素联合治疗市场成长与趋势：

Grand View Research最新报告显示，预计2030年全球青蒿素联合治疗市场规模将达10.187亿美元，2024年至2030年复合年增长率为8.2%。

ACT 采用率的提高和政府抗击疟疾流行的倡议的不断增加预计将推动市场成长。此外，管道扩张和新产品核准正在推动市场。

目前，世卫组织建议六种治疗併发症疟疾的联合疗法：蒿甲醚-本芴醇（AL）、青蒿琥酯-阿莫地喹（AS-AQ）和青蒿素）。 ACT的优点是疗效高、抗药性细菌发生率低。多年来，青蒿素联合治疗的使用范围显着扩大。 2016年，ACT在近80个国家被用作第一线治疗。

印度和中国等新兴製药国家不断增加的研发倡议正在推动 ACT 的采用率。肯亚、乌干达、奈及利亚和刚果等疟疾流行国家不断增长的需求可望扩大市场。新抗疟疾药的研发管线正在扩大，其中一些药物最近已推出。这些是推动 ACT 市场发展的一些因素。

世界卫生组织指出，ACT 是治疗最严重的併发症疟疾的必要方法，也是最好的治疗方法。建议使用 ACT，而不是磺胺多辛-乙胺嘧啶、Chloroquine和单药青蒿素等其他治疗方法。

疟疾是全世界最具破坏性的疾病之一，每年报告的新病例超过 2 亿例。根据 Medicines Malaria Venture (MMV) 的数据，2016 年全球总合445,000 人死于疟疾。全球疟疾盛行率持续上升，预计气候变迁将加速这一趋势。

青蒿素联合治疗市场报告亮点：

  • 蒿甲醚+本芴醇将占据市场主导地位，2023年将占37.1%的份额。对蒿甲醚+苯芴醇的需求不断增长，是因为其在治疗併发症疟疾方面具有卓越的功效和安全性。
  • 北美青蒿素联合治疗市场在2023年占据最大的市场收益占有率，为37.7%。需求增加主要是由于输入性疟疾病例数量不断增加以及对有效治疗方案的需求。
  • 亚太地区青蒿素联合治疗市场预计在预测期内将以最快的复合年增长率成长。亚太地区对青蒿素联合治疗（ACT）的需求正在增加。
  • 由于疟疾死灰復燃以及对传统抗疟疾药的抗药性不断增加，亚太地区的疟疾呈现上升趋势。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章青蒿素联合治疗市场变数、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 青蒿素联合治疗市场分析工具
    • 波特的分析
    • PESTEL分析

第四章青蒿素联合治疗市场：类型估计和趋势分析

  • 细分仪表板
  • 青蒿素联合治疗市场：类型变异分析，2023 年和 2030 年
  • 蒿甲醚 + 苯芴醇
  • 青蒿琥酯+阿莫地喹
  • 青蒿素+哌喹
  • 青蒿琥酯+甲氟喹
  • 青蒿琥酯+磺胺多辛-乙胺嘧啶
  • 离胺酸咯萘啶
  • 其他的

第五章青蒿素联合治疗市场：区域估计与趋势分析

  • 2023年及2030年青蒿素联合治疗市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第六章 竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Advanced Micro Devices
    • Novartis AG
    • Sanofi SA
    • Cipla Ltd.
    • KPC Pharmaceuticals
    • Fosun Pharmaceutical（Guilin Pharmaceutical）
    • Ajanta Pharma
    • Ipca Laboratories Ltd.
    • Desano Inc.
    • Hovid Berhad
    • Mylan
简介目录
Product Code: GVR-2-68038-592-2

Artemisinin Combination Therapy Market Growth & Trends:

The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.

Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.

Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.

WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.

Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.

Artemisinin Combination Therapy Market Report Highlights:

  • Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
  • North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
  • Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
  • Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Artemisinin Combination Therapy Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Artemisinin Combination Therapy Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Artemisinin Combination Therapy Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Artemisinin Combination Therapy Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Artemether+Lumefantrine
    • 4.3.1. Artemether+Lumefantrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Artesunate+Amodiaquine
    • 4.4.1. Artesunate+Amodiaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Dihydroartemisinin+Piperaquine
    • 4.5.1. Dihydroartemisinin+Piperaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Artesunate+Mefloquine
    • 4.6.1. Artesunate+Mefloquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Artesunate+Sulfadoxine-Pyrimethamine
    • 4.7.1. Artesunate+Sulfadoxine-Pyrimethamine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Pyronaridine-Artesunate
    • 4.8.1. Pyronaridine-Artesunate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Other
    • 4.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Artemisinin Combination Therapy Market: Regional Estimates & Trend Analysis

  • 5.1. Artemisinin Combination Therapy Market Share, By Region, 2023 & 2030 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Canada Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.4. Mexico
      • 5.2.4.1. Mexico Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. U.K.
      • 5.3.2.1. U.K. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Germany Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. France Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Spain
      • 5.3.5.1. Spain Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Italy
      • 5.3.6.1. Italy Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Sweden
      • 5.3.7.1. Sweden Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Norway
      • 5.3.8.1. Norway Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Denmark
      • 5.3.9.1. Denmark Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. China
      • 5.4.2.1. China Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Japan Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. India Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Australia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Thailand Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Argentina
      • 5.5.3.1. Argentina Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Saudi Arabia
      • 5.6.2.1. Saudi Arabia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. UAE
      • 5.6.3.1. UAE Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. South Africa
      • 5.6.4.1. South Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Kuwait Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis by Key Market Participants
  • 6.2. Company Categorization
  • 6.3. Company Heat Map Analysis
  • 6.4. Company Profiles
    • 6.4.1. Advanced Micro Devices
      • 6.4.1.1. Participant's Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Recent Developments/ Strategic Initiatives
    • 6.4.2. Novartis AG
      • 6.4.2.1. Participant's Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Recent Developments/ Strategic Initiatives
    • 6.4.3. Sanofi S.A.
      • 6.4.3.1. Participant's Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Recent Developments/ Strategic Initiatives
    • 6.4.4. Cipla Ltd.
      • 6.4.4.1. Participant's Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Recent Developments/ Strategic Initiatives
    • 6.4.5. KPC Pharmaceuticals
      • 6.4.5.1. Participant's Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Recent Developments/ Strategic Initiatives
    • 6.4.6. Fosun Pharmaceutical (Guilin Pharmaceutical)
      • 6.4.6.1. Participant's Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Recent Developments/ Strategic Initiatives
    • 6.4.7. Ajanta Pharma
      • 6.4.7.1. Participant's Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Recent Developments/ Strategic Initiatives
    • 6.4.8. Ipca Laboratories Ltd.
      • 6.4.8.1. Participant's Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Recent Developments/ Strategic Initiatives
    • 6.4.9. Desano Inc.
      • 6.4.9.1. Participant's Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Recent Developments/ Strategic Initiatives
    • 6.4.10. Hovid Berhad
      • 6.4.10.1. Participant's Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Recent Developments/ Strategic Initiatives
    • 6.4.11. Mylan
      • 6.4.11.1. Participant's Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Recent Developments/ Strategic Initiatives